|
Market Closed -
Nasdaq
01:30:00 27/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 76.99 USD | +0.03% |
|
-.--% | +182.32% |
| 31/08 | Forte Biosciences, Inc.(NasdaqGM:FBRX) dropped from Russell 3000E Growth Index | CI |
| 31/08 | Forte Biosciences, Inc.(NasdaqGM:FBRX) dropped from Russell Microcap Growth Index | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Net Income | -2.17Cr | -1.39Cr | -3.15Cr | -3.55Cr | -6.94Cr | |||
D&A | 36T | - | 9T | 39T | 64T | |||
Operating Income | -2.15Cr | -1.39Cr | -3.25Cr | -3.66Cr | -7.07Cr | |||
EBT | -2.17Cr | -1.39Cr | -3.15Cr | -3.55Cr | -6.83Cr | |||
CAPEX | - | - | -88T | -37T | -1L | |||
Income Tax Expense | - | - | - | - | 10.37L | |||
Interest Expense | - | - | - | - | - | |||
Total Assets | 4.33Cr | 4.2Cr | 3.9Cr | 6.16Cr | 8.28Cr |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Operating Income | -2.15Cr | -1.39Cr | -3.25Cr | -3.66Cr | -7.07Cr | |||
Net Income | -2.17Cr | -1.39Cr | -3.15Cr | -3.55Cr | -6.94Cr | |||
EBT | -2.17Cr | -1.39Cr | -3.15Cr | -3.55Cr | -6.83Cr | |||
CAPEX | - | - | -88T | -37T | -1L | |||
D&A | 36T | - | 9T | 39T | 64T | |||
Income Tax Expense | - | - | - | - | 10.37L | |||
Interest Expense | - | - | - | - | - | |||
Total Assets | 4.33Cr | 4.2Cr | 3.9Cr | 6.16Cr | 8.28Cr |
- Stock Market
- Stocks
- FBRX Stock
- Financials Forte Biosciences
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
